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Available online 7 June 2016The implementation of the ICH S7B and E14 guidelines has been successful in preventing the introduction of po-
tentially torsadogenic drugs to the market, but it has also unduly constrained drug development by focusing on
hERG block and QT prolongation as essential determinants of proarrhythmia risk. The Comprehensive in Vitro
Proarrhythmia Assay (CiPA) initiative was established to develop a new paradigm for assessing proarrhythmic
risk, building on the emergence of new technologies and an expanded understanding of torsadogenic mecha-
nisms beyond hERG block. An international multi-disciplinary team of regulatory, industry and academic scien-
tists are working together to develop and validate a set of predominantly nonclinical assays and methods that
eliminate the need for the thorough-QT study and enable a more precise prediction of clinical proarrhythmia
risk. The CiPA effort is led by a Steering Team that provides guidance, expertise and oversight to the variouswork-
ing groups and includes partners from US FDA, HESI, CSRC, SPS, EMA, Health Canada, Japan NIHS, and PMDA. The
working groups address the three pillars of CiPA that evaluate drug effects on: 1)humanventricular ionic channel
currents in heterologous expression systems, 2) in silico integration of cellular electrophysiologic effects based on
ionic current effects, the ion channel effects, and 3) fully integrated biological systems (stem-cell-derived cardiac
myocytes and the human ECG). This article provides an update on the progress of the initiative towards its target
date of December 2017 for completing validation.
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The risk of approving drugswith the potential to produce Torsade de
pointes (TdP) in patients has effectively been eliminated by evaluating
their ability to block the human ether-à-go-go related gene (hERG)
channel in vitro, and prolong ventricular repolarization and the QTc in-
terval of the ECG in preclinical studies and clinical trials (Anonymous,
2005a; Anonymous, 2005b) However, the high sensitivity of this ap-
proach comes with low speciﬁcity. As a result, many drugs with effects
on hERG andQTc prolongation but little actual TdP risk are deprioritized
or excluded from further development or, if approved, see their clinical
use limited by inappropriate warnings in product labeling.
The cause for the low speciﬁcity of the current ICH S7B/E14 approach
is generally understood to be the result of focusing on only one of the
many ion channels governing ventricular repolarization, and the inade-
quacy of the QTc interval as a surrogate marker of actual proarrhythmic
risk. The duration of ventricular repolarization is determined by a ﬁne
balance between inward (depolarizing) and outward (repolarizingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
CiPA compounds.
A list of the CiPA compound test set and calibration drugs
High risk Intermediate risk Low risk
Azimilide Astemizole Diltiazema
Bepridila Chlorpromazinea Loratadine
Dofetilidea,b Cisapridea Metoprolol
Ibutilide Clarithromycin Mexiletinea
Quinidinea Clozapine Nifedipineb
Vandetanib Domperidone Nitrendipine
Disopyramide Droperidol Ranolazinea
D,l Sotalola Terfenadinea Tamoxifen
Pimozide Verapamila
Risperidone
Ondansetrona
a 12 compound test set.
b Myocyte calibration compounds.
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net outward current exceeds the amount of net inward current during
the cardiac action potential plateau, repolarization occurs. The risk of
proarrhythmia increases when repolarization is delayed to such a de-
gree that inward currents can be triggered and generate new excitatory
waveforms. While drug block of the hERG/IKR channel plays a critical
role in delaying repolarization (see Rampe and Brown, 2013, for a re-
view), activation of inward late sodium and/or calcium currents are
needed to trigger a proarrhythmia response. Drugs that affect both in-
ward and outward cardiac currents (e.g. verapamil, ranolazine) may
therefore have effects on repolarization and the QTc interval, but not
be associated with the generation of TdP due to the blockade of inward
currents. Because experimental studies and in silico reconstructions of
ventricular repolarization have shown differences across species in the
ionic currents underlying repolarization and proarrhythmia (O'Hara
and Rudy, 2012), there is a need to use human-based studies to assess
accurately the clinical risk of delayed repolarization and proarrhythmia.
Some pharmaceutical developers now appreciate these issues and,
to varying extents, factor ion channel activity beyond hERG into devel-
opment decisions (Gintant et al., 2016, Polak et al., 2015). However,
the premature termination of drugs due to hERG and/or QT effects
that might have favorable beneﬁt to risk ratios remains common. The
Comprehensive in Vitro Proarrhythmia Assay (CiPA) is being developed
to place this integrated, mechanistic assessment of risk on a footing
solid enough to inform regulatory decision-making, and efﬁcient
enough to be deployed during the drug discovery phase. It is envisioned
that drugs that are assessed as being at low likelihood for causing TdP
may receive benign labeling even if they have some QT prolonging
effects.
The CiPA pathway consists of three main elements, 1) assessment of
drug effects on the critical human ventricular ion channel currents, 2) in
silico integration of the ion channel effects to determine the net effects
on the cardiac action potential, and 3) a check for discrepancies in fully
integrated biological systems (stem-cell-derived cardiac myocytes and
the human ECG) (Sager et al., 2014).
A Steering Team convenes working groups to address each of the
three CiPA elements and drives the initiative forward. The CiPA Steering
Team consists of partners from theUnited States Food and Drug Admin-
istration (US FDA), Health and Environmental Sciences Institute (HESI),
Cardiac Safety Research Consortium (CSRC), Safety Pharmacology Soci-
ety (SPS), EuropeanMedicines Agency (EMA), Health Canada, JapanNa-
tional Institute of Health Sciences (NIHS), and Pharmaceuticals and
Medical Devices Agency (PMDA). These organizations each provide pro-
ject administration support aswell as scientiﬁc experts to populate each
working group. Through this complex network of consortia and experts,
novel data are being generated for the CiPA initiative. This article de-
scribes theprogressmade todate and theplan to bringCiPA into general
use.
2. Compound selection
To support this effort, a set of compounds with well-deﬁned cardiac
electrophysiology and known clinical characteristicswas identiﬁed by a
subteam of expert clinicians, safety pharmacologists, and cardiac elec-
trophysiologists who discussed, selected and categorized 28 com-
pounds into high, intermediate and low risk of Torsade de Pointes
(TdP) based on published reports, analysis of the FDA adverse event
reporting system (AERS) database, other data sources and expert opin-
ion. The set of 28 drugs was divided into a set of 12 drugs to be used for
CiPA training and calibration, with the remaining 16 used for CiPA
validation.
3. Ion channel
The Ion Channel Working Group (ICWG), sponsored by the Safety
Pharmacology Society (SPS), was established in December 2013. Itsprimary role is to work in close collaboration with the In SilicoWorking
Group (ISWG) in providing ion channel support for the development of
a computer model of the adult human ventricular myocyte, to be used
as part of the CiPA initiative in predicting the clinical risk of drug-
induced TdP. Originally composed of a number of expert electrophysiol-
ogists from various pharmaceutical companies, contract research orga-
nizations and academic institutions, the ICWG has morphed into a
smaller and nimbler Rapid Response Team (RRT) empowered with
the task of addressing emerging issues affecting the ﬂuid interaction be-
tween the ICWG and the ISWG, while focusing on the timely delivery of
supporting data. The original remit of the ICWG was: 1) to select key
cardiac ion channels to include in the CiPA evaluation; 2) to develop ro-
bust, reliable and reproducible voltage clamp protocols required to gen-
erate data allowing the training and validation of the in silicomodel; 3)
to deﬁne which biophysical and/or pharmacological properties of the
channels to study for drug effects in order to optimize the predictivity
of the model (e.g., potency (IC50), kinetic of block, rate/use/voltage de-
pendence) and; 4) to deﬁne the requirements needed to transition the
various ion channel protocols frommanual to automated high through-
put (HT) patch clamp platforms, in order to adapt to the screening envi-
ronment present in most pharmaceutical companies. It is believed that
developing a standardized protocol for each ion channel will, in itself,
be of signiﬁcant beneﬁt to the ﬁeld since many different protocols
with varying results are currently in use.
Seven recombinant human channels expressed in replicating cell
lines were selected to be studied. The selection was based partly on
the knowledge of their fundamental roles in deﬁning the human cardiac
action potential duration (APD) and documented contribution to cardi-
ac arrhythmias (Moreau et al., 2013; Belardinelli et al., 2006; Workman
et al., 2012; January and Riddle, 1989; Kim et al., 2016; Varro and
Baczko, 2011; Lengyel et al., 2007; Stengl et al., 2003; Virag et al.,
2009), together with the information obtained from an SPS survey, ex-
ploring the diversity of ion channels screened in the pharmaceutical in-
dustry as part of cardiovascular safety de-risking strategies. The SPS
survey was conducted in 2013 to gather additional information about
pharmaceutical practices with regards to ion channel screening in non-
clinical drug development phases. Results were presented at the CSRC/
HESI/SPS/FDA joint meeting on December 11, 2014, but remain unpub-
lished. The selected channels include: IKr (hERG), ICa (L-type; Cav1.2),
INa (Nav1.5 peak and late current); ITO (Kv4.3); IKs (KCNQ1 + KCNE1),
and IK1 (Kir2.1). Following the selection, the ICWG set out to design
standardized voltage clamp protocols for each of these channels.
In addition to developing protocols, the ICWG and ISWG collaborat-
ed to deﬁne a “minimally acceptable” dataset needed for modeling. Ac-
cordingly, the two groups initially agreed to focus on hERG, and identify
a protocol allowing the characterization of potency and dynamic block
properties of the compounds included in the test set of 12 drugs select-
ed for training and validation of the model (Table 1). While adopting a
single voltage clamp protocol to be used at both room and physiologic
17T. Colatsky et al. / Journal of Pharmacological and Toxicological Methods 81 (2016) 15–20(35–37 °C) temperatures proved to be a challenge, it was also an impor-
tant decision since the potency of some hERG blockers was previously
shown to display marked sensitivity to stimulus protocol and/or mea-
surement temperature (Kirsch et al., 2004; Milnes et al., 2010; Yao et
al., 2005;). Therefore, adoption of a single, standardized, protocol is ex-
pected to reduce variability. A few iterations were required before the
group settled on the current version of the protocol (Milnes et al.,
2010). hERG data are currently being generated using the manual volt-
age clamp technique because it is considered by most as the gold stan-
dard approach in industry, and since it will serve as the foundation for
the rest of the in silicowork. In an effort tomeet theprojectedDecember
2017 deadline, only potency data will be generated for all remaining,
non-hERG, channels. When used in combination with the hERG results,
these data will prove critical in assessing the model's performance, and
help deﬁnewhether additional ion channel studies are needed in the fu-
ture to optimize it. A signiﬁcant beneﬁt deriving from this effort will be
the establishment of best practices for ion channel studies used to char-
acterize drug effects on cardiac repolarization.
Clearly, the protocols developed by the ICWG and used for the eval-
uation of non-hERG ion channels will need to be adapted for use on au-
tomated HT platforms, and this transition may pose substantial issues,
at least for some of the ion channels. To that end, theHESI Cardiac Safety
Proarrhythmia Working Group has recently sponsored a new initiative
across multiple research sites with the following objectives: 1)
assessing the feasibility of transferring protocols developed for manual
clamp work to HT platforms; 2) understanding the advantages, draw-
backs and limitations of the various platforms used across the industry
and; 3) developing data quality standards equivalent to that obtained
with the manual work. While a strategy remains to be mapped out in
details, the original plan is to study the same test set of 12 drugs onmul-
tiple cardiac ion channels across different HT platforms, and acrossmul-
tiple different sites using the same platforms. This ﬁrst data set will be
used to benchmark the systems and will also be shared with the ISWG
as part of the calibration phase in order to assess the model's perfor-
mance. Thereafter, the remaining 16 compounds from the original list
of 28 will also be studied, and the data handled similarly both to bench-
mark the systems, as well as contribute to the calibration phase of the
model. The compoundswill be single-sourced for distribution, and stan-
dardized procedures (voltage protocols, data quality standards, concen-
trations tested)will be established and used across all sites. A number of
metricswill be assessed including potency, reproducibility and variabil-
ity of pharmacological effects. It is anticipated that data for the 12 drug
test set will be completed by 2Q 2016, and the remaining drugs by the
end of 4Q16. Data will prove invaluable in assessing data quality, in set-
ting expectations, and in establishing credibility in the HT approach for
generating key data to be used in the validation of the in silicomodel for
deﬁning proarrhythmic risk.
4. In silico model of an adult human ventricular myocyte
A central component of the CiPA paradigm is the use of an in silico
model of the adult human ventricular myocyte to integrate patch
clamp data onmultiple ion channels and extract a metric that can clear-
ly rate a drug as having high,moderate or little/no risk of producing TdP
in patients. The riskmetric is intended to bemechanistic, experimental-
ly veriﬁable, and directly related to the changes in cellular electrical ac-
tivity known to be associated with TdP and its triggers.
An expert group reviewed several models and ultimately, the
O'Hara-Rudy (ORd) model was adopted as the starting point for devel-
oping an in silico model suitable for regulatory decision making based
on its use of data from undiseased human ventricular cells (O'Hara et
al., 2011). The model development strategy was framed by the follow-
ing requirements: 1) the context of use for the model should be clearly
deﬁned and focused on assessment of the relative risk of clinical drug-
induced TdP; 2) model parameters should be linked to and constrained
by actual experimental data; 3) the methods used to generate theseexperimental data should build on current pharmaceutical industry
“best practices” for cardiac safety assessment (Gintant et al., 2016,
Polak et al., 2015); 4) all modeling assumptions should be transparent
and veriﬁable; and 5) rather than simply identifying a drug as
torsadogenic or non-torsadogenic, the metric used to assess relative
TdP risk should provide a clear separation of the reference drugs into
three distinct risk categories. The 12 drug training set was used to eval-
uate “minimal” standardized patch clamp protocols to characterize ion
channel pharmacology and identify the data quality criteriamost critical
for reliably informing model parameterization and risk predictions.
The ﬁrst challenge arose in recognition that simply characterizing
the concentration-dependence of hERG block as an IC50 would not be
sufﬁcient for calculating the relative clinical risk of TdP. There is much
evidence indicating that drugs can interact with the hERG channel in a
time-, voltage- and state-dependentmanner (Di Veroli et al., 2014). Be-
cause the ORdmodel simulates activity at normal physiological temper-
atures and because most industry-generated hERG data are obtained at
room temperature, a dynamicmodel of the hERG channel with temper-
ature-sensitive transitions between channel states was developed by
modifying the Markov model published by Di Veroli et al. (2013). The
modiﬁed hERG model was able to reproduce quantitatively various
temperature-induced changes in gating processes occurring at room
and physiological temperatures, including changes in the rate and volt-
age dependence of activation, inactivation and deactivation reproduced
(Li et al., 2016).When incorporated into theORdmodel, action potential
waveforms and electrical behaviors were also faithfully reproduced.
The second challengewas to develop and characterize a set of candi-
date metrics that could distinguish different levels of TdP risk. While
standardized patch clamp protocols and newmulti-channel pharmacol-
ogy data sets were being generated by the ICWG, initial in silico efforts
used IC50s for the various cardiac ion channels of interest from the patch
clamp data set generated by Crumb et al. (2016) and combinedwith dy-
namic hERG block data generated by the ICWG using manual patch
clamp methods at both room and physiological temperatures. The util-
ity of the classical riskmetrics, such asAPD90, triangulation of the action
potential waveform, and the appearance of early after depolarizations
(EADs),were evaluated, alongwithmore biophysicalmeasurements as-
sociated with action potential prolongation and torsadogenesis, such as
net repolarizing current and the likelihood and degree of drug trapping
within the hERG/IKr channel. There are some promising candidates
based in the limited data set of hERG blockers that have so far been sys-
tematically characterized, but a full and critical evaluation awaits com-
pletion of the new pharmacology studies on the CiPA training set
drugs. This work is ongoing and much of the hERG kinetic data will be
generated before the end of 2016. Completion dateswill reﬂect the con-
tinued interactions between the ISWGand ICWG to generate new phar-
macology data, assess the protocols used, and develop data quality
criteria.
An additional beneﬁt of the initial in silico modeling work is getting
feedback that can guide protocol improvements andestablish data qual-
ity requirements. As data generationmigrates frommanual to automat-
ed path clamping, data standards and quality criteria will become
increasingly important to ensure that model input parameters are de-
rived from reliable pharmacology data sets. Upon completion of the in
silico model, the plan is to make it available as open-source software
so that all sponsors will have access to the same resource.
5. Human stem cell-derived cardiomyocytes: present and future role
in the CiPA paradigm
The role of human cardiac stem cell derived cardiomyocytes (hSC-
CMs) within the CiPA paradigm is to conﬁrm in silico reconstructions
of the electrophysiologic effects of drugs. This will be accomplished by
evaluating the acute effects of drugs on the electrical activity of hSC-
CM's using higher throughput approaches that enable more compre-
hensive and robust assessments earlier in the drug discovery process.
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lar ﬁeld potentials of spontaneously active hSC-CMs using multielec-
trode array (MEA) platforms, or changes in the action potential
conﬁguration recorded optically using voltage-sensing dyes (VSD) or
integral membrane proteins (with the optical approaches providing
greater granularity regarding changes in the different phases of repolar-
ization). Both approaches report on integrated responses resulting from
drug effects onmultiple cardiac currents, pumps, and exchangers, some
of which cannot be easily or reliably measured using high throughput
planar patch clamp systems or modeled in silico. Consequently, it is ex-
pected that hSC-CMs would identify potential gaps in cellular electro-
physiologic effects (and likely not detected previously) that may
impact TdP risk assessments and warrant further assessment.
Numerous published studies have demonstrated the ability of
hSC-CMs to detect delayed repolarization elicited by drugs with
known effects on either hERG current or the clinical ECG (Clements
and Thomas, 2014; Gilchrist et al., 2015; Harris et al., 2013;
Hayakawa et al., 2014; Kitaguchi et al., 2016; Lu et al., 2015;
Matsuo et al., 2015; Nozaki et al., 2014; Uesugi et al., 2014).While in-
formative, such studies may be biased in regards to proarrhythmic
risk of selected compounds, may be conducted unblinded, and
often involve small sets of compounds. Further, the use of different
cells, cultured for different times, along with different protocols ap-
plied across varied technology platforms (e.g., microelectrode
array, voltage-sensing dyes and proteins, transmembrane record-
ings, and calcium sensing indicators) make comparisons of results
across studies difﬁcult because of lack of standardization and analyt-
ical calibration of assay sensitivity. To address these issues, a pilot
study was conducted by the Health and Environmental Sciences In-
stitute (HESI) Cardiac Safety Committee Myocyte Subteam to evalu-
ate reproducibility and variability of electrophysiologic responses
across cells, platforms and volunteer study sites for 8 compounds,
Mexiletine, Nifedipine, E-4031, JNJ-303, Flecanide, Moxiﬂoxacin,
Quinidine and Ranolazine. Overall, most sites detected changes in re-
polarization consistent with clinical ﬁndings, with the greatest
source of variability attributed to study site.
More recently, the HESI Myocyte Subteam was awarded a Broad
Area Announcement Grant from the FDA to extend the pilot study to a
larger set of 28 compounds categorized according to high, intermediate,
and low/no risk of proarrhythmia based on clinical ﬁndings (see
Compound selection Section, above). The effects of these CiPA reference
standards will be evaluated by a core group in this Phase II Validation
study across four MEA and two VSO technology platforms using two
commercially viable hSC-CM preparations. Results will be compared
with prospective in silico reconstructions (based on voltage clamp stud-
ies) and published studies employing hSC-CMs fromnon-core laborato-
ries and consortia for the same 28 compounds. Anticipated start date for
experimental work is 2Q 2016, with analysis completed by 4Q2016 and
data sharing/manuscript preparation in early 2017.
In 2013, a parallel effort began in Japan where a Japanese research
project conducted by the National Institute of Health Sciences (NIHS),
with support from the ministry of Health, Labour and Welfare, stan-
dardized a protocol using an MEA platform for inter-facility validation
among labs from industry, government and academia (Nakamura et
al., 2014). The Japanese iPS Cardiac Safety Assessment (JiCSA) was
established in 2014 to perform larger scale validation studies (4
industries+NIHS) in collaborationwith the Japan Safety Pharmacology
Society. JiCSA has now completed the collection of 60 compounds
resulting in more optimized and improved protocols for the validation
study (Asakura et al., 2015). The 60 compounds overlap with almost
all of the 28 CiPA compounds with the exception of Azimilide since it
was not available in Japan when JiCSA started their validation study.
The results have shown good concordance in predicting TdP risk as re-
ported in CredibleMeds, and good agreement with the HESI Myocyte
Subteampilot study data. These results will be sharedwith the CiPA ini-
tiative under the data sharing policy. JiCSA will also participate in thePhase II Validation study with the Myocyte Subteam and compare
data across HESI Myocyte Subteam sites.
It is now appreciated that hSC-CMs from different sources and
vendors display different electrophysiologic phenotypes which
may reﬂect (at least in part) different levels of maturation (Liu et
al., 2016; van den Heuvel et al., 2014). Such differences (which are
not unlike observations from tissues derived from different aged an-
imals or across species) may affect pharmacologic responses and
thereby inﬂuence assay sensitivity and subsequent risk assessments.
Further, with daily advances being made in understanding cardiac
development, myocyte signaling, and tissue engineering, it is recog-
nized that hSC-CMs are evolving as an experimental preparation to-
wards a more adult-like phenotype. To control for present (and
anticipated future) electrophysiologic advances that may inﬂuence
pharmacologic responses, the myocyte validation efforts will include
a set of four calibration compounds (the IKr blocker dofetilide, the
late sodium current blocker lidocaine, the calcium current blocker
nifedipine, and the IKs current blocker JNJ303) selected to demon-
strate sensitivity to four key currents modulating ventricular repo-
larization. Electrophysiologic responses to these calibration
standards (alongside those of novel drug candidates) provide con-
text to electrophysiologic effects elicited by novel drug candidates
assessed in parallel (an advantage provided by the higher through-
put screening approach), and provide for benchmarking assay sensi-
tivity of present and future hSC-CMs in the evolving CiPA paradigm.
As advances in understanding cardiac development grow along-
side successes in regenerative medicine, it is anticipated that the
role of evolving hSC-CMs preparations within CiPA will move away
from conﬁrming in silico reconstructions (and detecting gaps not an-
ticipated from simpler voltage clamp studies.) The role of hSC-CMs
will move towards a platform that more closely resembles mature
electrophysiologic phenotypes from normal (and diseased) states,
enabling more global risk assessments pertinent to normal popula-
tions (as well as individualized risk assessments for patients with in-
jured or diseased myocardium.)
6. Clinical Phase I ECGs
CiPA proposes to utilize an ECG assessment in early clinical Phase 1
studies (single or multiple ascending dose studies) to determine if
there are unexpected ion channel effects compared to the preclinical
ion channel data, such as due to a human-speciﬁc metabolite or protein
binding. The CiPA Phase 1 ECG working group identiﬁed key criteria for
any new CiPA biomarker that must: 1) add additional information be-
yond PR, QRS and QTc, 2) differentiate selective hERG blocking drugs
from multi-ion channel blocking drugs (i.e. hERG + calcium and/or
late sodium block), 3) be corrected for heart rate if needed and 4)
have sufﬁcient power to detect changes in small sample sizes with ex-
posure-response analysis.
The CiPA working group considered 12 potential ECG biomarkers,
which are summarized in Vicente et al. (2015.) Through analysis of
prior clinical studies, the CiPA Phase 1 ECG working group identiﬁed
the heart rate corrected J-Tpeak interval (J-Tpeakc) as the best biomark-
er to differentiate QT prolonging drugs with selective hERG block from
QT prolonging drugs with hERG and late sodium or calcium current
block (Johannesen et al., 2014 and2016). In addition, the J-Tpeakc inter-
val can be corrected for heart rate and has similar variability as QTc,
leading to similar power as QTc to differentiate changes with expo-
sure-response analysis in the small sample sizes typical of Phase 1
studies.
The CiPA Phase 1 ECG working group held a public workshop spon-
sored by the Cardiac Safety Research Consortium in April 2016 where
the current status and validation and implementation strategy were
discussed. Next steps include: 1) ﬁnalizing a statistical framework that
can be applied in small sample sizes with exposure-response analysis
similar to QTc, 2) extending analysis to a larger number of prior clinical
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analysis algorithm as open-source code to facilitate wide-spread testing
and performing a multi-site reproducibility study and 4) planning and
completing a conﬁrmatory prospective study in 2017 with a small sam-
ple size design similar to ﬁrst-in-human single or multiple ascending
dose studies. It is anticipated that this prospective study will include
six drugs with a combination of selective hERG block, multi-ion channel
block and no ion channel effect drugs.
7. Next steps
Over 2015, various CiPA group leads have had an opportunity to
share with the ICH S7B/E14 Discussion Group (upon which several
CiPA Steering Committee members also serve) materials relating to
the rationale and approach being taken in the CiPA project, and achiev-
ing some degree of concurrence on the general path forward. The CiPA
Steering Committee is optimistic that this interaction will speed accep-
tance of this alternative pathway for assessment of proarrhythmic po-
tential for regulatory purposes.
The Steering Committee is also optimistic that the work outlined
here can be completed by the end of 2017. How quickly we advance
to that goal can be monitored through quarterly updates posted to its
project website (www.CiPAproject.org) and a planned public meeting
in December 2016.
Soon thereafter, therewould be a strong interest in at least the US, in
carefully evaluating approved drugs that show evidence of being other
than selective hERG blockers, with the expectation that application of
CiPA will result in many of them having their current labeling changed
to more benign language.
8. Conclusions
CiPA is anticipated to address a major conundrum in drug devel-
opment. While the current focus on hERG current block and QT pro-
longation has been successful in drugs not being approved with
unanticipated proarrhythmic effects, its reliance on non-highly spe-
ciﬁc biomarkers has negatively impacted drug development due to
the premature termination of drugs with otherwise positive risk-
beneﬁt ratios. This represents a signiﬁcant public health issue. CiPA's
mechanistic approach is focused on the key issue- what is the likeli-
hood that a particular drug is proarrhythmic. Since the initial public
discussion of CiPA in July 2013, there has been a concerted interna-
tional effort to deﬁne, standardize, and validate the human ion chan-
nel assays, deﬁne the metrics of the in silico model, test and validate
hSC-CM-based approaches, and deﬁne and test Phase 1 ECG bio-
markers. Signiﬁcant scientiﬁc progress has been made and the CiPA
effort is on track to complete the necessary work by the end of
2017. The CiPA Steering Committee is providing the ICH S7B/E14 Dis-
cussion Group with on-going updates on working group progress
and seeking input from ICH on the regulatory implementation of
CiPA as the effort evolves over the next ~1.5 years.
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